# A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

> **NCT06178991** · PHASE3 · COMPLETED · sponsor: **BioNTech SE** · enrollment: 8795 (actual)

## Conditions studied

- Influenza
- COVID-19

## Interventions

- **BIOLOGICAL:** Influenza and COVID-19 Combination A
- **BIOLOGICAL:** Licensed influenza vaccine
- **BIOLOGICAL:** COVID-19 Vaccine
- **BIOLOGICAL:** Influenza and COVID-19 Combination B
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Investigational influenza vaccine

## Key facts

- **NCT ID:** NCT06178991
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-20
- **Primary completion:** 2024-11-26
- **Final completion:** 2024-11-26
- **Target enrollment:** 8795 (ACTUAL)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06178991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06178991, "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06178991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*